Announced Wed, 29 Apr · 16:20 IST

Pursuant to SEBI Circular SEBI/HO/CFD/-POD-2024/185 dated 31-12-2024 read with BSE Circular No. 20250102-4 we are submitting herewith the Integrated Filing (Financial)for the Quarter ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.0%1-day move
₹47.84
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.0+4.5-0.3+3.5+6.6+4.5-8.0+17.3+74.1
Up moveDown movePending
AI summary

Colinz Laboratories Ltd has submitted its Integrated Filing (Financial) for Q4 and the full year ended 31st March 2026 to BSE, in compliance with SEBI circular requirements. The filing includes Financial Results (Annexure A) along with several standard disclosures. Annexures B through E are marked as 'Not Applicable', indicating no deviations in fund usage, no outstanding loan defaults, no reportable related party transactions, and no audit qualifications in the financial statements. The actual financial numbers and performance details are contained in Annexure A which is not included in this document. The filing was signed by Director Vijaya Mani.

Likely market impact

The 'Not Applicable' status on key annexures suggests a clean filing with no material red flags such as debt defaults, audit qualifications, or related party transaction concerns. However, actual financial performance data would be needed to assess revenue, profitability, and cash flow trends for the period.